GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,647.00p
   
  • Change Today:
      7.50p
  • 52 Week High: 1,711.20p
  • 52 Week Low: 1,316.00p
  • Currency: UK Pounds
  • Shares Issued: 4,144.88m
  • Volume: 504,886
  • Market Cap: £68,266m
  • RiskGrade: 129

WHO warns 'silver bullet' for Covid-19 may never come

By Caoimhe Toman

Date: Monday 03 Aug 2020

LONDON (ShareCast) - (Sharecast News) - The World Health Organization warned on Monday that there is a possibility that a "silver bullet" to combat Covid-19 may never come despite the existing strong hopes for a vaccine.
The WHO also said that the road to normality could take a lot longer than initially expected, especially as some nations that thought they were over the worst were now experiencing a resurgence.

WHO Director-General Tedros Adhanom Ghebreyesus said: "The message to people and governments is clear: 'Do it all'."

Speaking from the UN body's headquarters in Geneva, he urged people to wear face masks as an act of solidarity with other people: "A number of vaccines are now in phase three clinical trials and we all hope to have a number of effective vaccines that can help prevent people from infection. However, there's no silver bullet at the moment - and there might never be."

"There are concerns that we may not have a vaccine that may work, or its protection could be for just a few months, not more. But until we finish the clinical trials, we will not know," he added.

The WHO head also said that its advance investigation team had not yet returned from China, where the virus had originated.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,647.00p
Change Today 7.50p
% Change 0.46 %
52 Week High 1,711.20p
52 Week Low 1,316.00p
Volume 504,886
Shares Issued 4,144.88m
Market Cap £68,266m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
81.12% below the market average81.12% below the market average81.12% below the market average81.12% below the market average81.12% below the market average
81.13% below the sector average81.13% below the sector average81.13% below the sector average81.13% below the sector average81.13% below the sector average
Price Trend
32.95% above the market average32.95% above the market average32.95% above the market average32.95% above the market average32.95% above the market average
71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average
Income
43.54% above the market average43.54% above the market average43.54% above the market average43.54% above the market average43.54% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
25.73% below the market average25.73% below the market average25.73% below the market average25.73% below the market average25.73% below the market average
40.54% above the sector average40.54% above the sector average40.54% above the sector average40.54% above the sector average40.54% above the sector average

What The Brokers Say

Strong Buy 8
Buy 5
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 22-Feb-24 16-Nov-23
Paid 11-Apr-24 11-Jan-24
Amount 16.00p 14.00p

Trades for 23-Apr-2024

Time Volume / Share Price
10:28 417 @ 1,647.00p
10:28 177 @ 1,647.50p
10:28 179 @ 1,647.50p
10:28 447 @ 1,647.50p
10:28 636 @ 1,647.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page